

Current Medical Diagnosis & Treatment 1987

Edited By

MARCUS A. KRUPP, MD

STEVEN A. SCHROEDER

LAWRENCE M. HERNEY

05998

R50

K94

1987

Current Medical Diagnosis & Treatment 1987

Edited By

MARCUS A. KRUPP, MD

Clinical Professor of Medicine, Emeritus
Stanford University School of Medicine (Stanford)
Director of Research Institute
Palo Alto Medical Foundation (Palo Alto)

STEVEN A. SCHROEDER, MD

Professor of Medicine and Chief
Division of General Internal Medicine
University of California (San Francisco)

LAWRENCE M. TIERNEY, JR., MD

Professor of Medicine
University of California (San Francisco)
Assistant Chief of Medical Service
Veterans Administration Medical Service (San Francisco)

with Associate Authors



**Appleton
& Lange**

Norwalk, Connecticut / Los Altos, California

0-8385-1413-8

Notice: Our knowledge in clinical sciences is constantly changing. As new information becomes available, changes in treatment and in the use of drugs become necessary. The author(s) and the publisher of this volume have taken care to make certain that the doses of drugs and schedules of treatment are correct and compatible with the standards generally accepted at the time of publication. The reader is advised to consult carefully the instruction and information material included in the package insert of each drug or therapeutic agent before administration. This advice is especially important when using new or infrequently used drugs.

Copyright © 1987 by Appleton & Lange
A Publishing Division of Prentice-Hall
Copyright © 1962 through 1986 by Lange Medical Publications

Spanish Edition: Editorial El Manual Moderno, S.A. de C.V.,
Av. Sonora 206, Col. Hipodromo, 06100-Mexico, D.F.

Italian Edition: Piccin Nuova Libreria, S.p.A., Via Altinate, 107,
35121 Padua, Italy

German Edition: Springer-Verlag GmbH & Co. KG, Postfach 10 52 80,
6900 Heidelberg 1, West Germany

Serbo-Croatian Edition: Savremena Administracija, Crnotravska 7-9,
11100 Belgrade, Yugoslavia

Portuguese Edition: Atheneu Editora São Paulo Ltda.,
Rua Marconi, 131 - 2.º andar, 01047 São Paulo, Brazil

Greek Edition: Gregory Parisianos, 20, Navarinou Street,
GR-106 80 Athens, Greece

Dutch Edition: Kooyker Scientific Publications B.V., Postbus 24,
2300 AA Leiden, The Netherlands

All rights reserved. This book, or any parts thereof, may not be used or reproduced in any manner without written permission. For information, address Appleton & Lange, 25 Van Zant Street, East Norwalk, Connecticut 06855.

87 / 10 9 8 7 6 5 4 3 2

Prentice-Hall of Australia, Pty. Ltd., Sydney
Prentice-Hall Canada, Inc.
Prentice-Hall Hispanoamericana, S.A., Mexico
Prentice-Hall of India Private Limited, New Delhi
Prentice-Hall International (UK) Limited, London
Prentice-Hall of Japan, Inc., Tokyo
Prentice-Hall of Southeast Asia (Pte.) Ltd., Singapore
Whitehall Books Ltd., Wellington, New Zealand
Editora Prentice-Hall do Brasil Ltda., Rio de Janeiro

ISSN: 0092-8682

ISBN: 0-8385-1413-8

PRINTED IN THE UNITED STATES OF AMERICA

Current
Medical
Diagnosis &
Treatment 1987

From inability to let well alone; from too much zeal for the new and contempt for what is old; from putting knowledge before wisdom, science before art and cleverness before common sense; from treating patients as cases; and from making the cure of the disease more grievous than the endurance of the same, Good Lord, deliver us.

—Sir Robert Hutchison

The Authors

Michael J. Aminoff, MD, FRCP

Professor of Neurology, University of California (San Francisco).

Robert B. Baron, MD

Assistant Clinical Professor of Medicine, University of California (San Francisco).

R. Laurence Berkowitz, MD

Clinical Assistant Professor of Plastic & Reconstructive Surgery, Stanford University School of Medicine (Stanford).

James J. Brophy, MD

Associate Clinical Professor of Psychiatry, University of California School of Medicine (San Diego).

Carlos A. Camargo, MD

Associate Professor of Clinical Medicine, Stanford University School of Medicine (Stanford); Director of Endocrine Clinic, Stanford University Hospital (Stanford).

Jerome E. Carbone, MD

(Bremerton, Washington)

Milton J. Chatton, MD

Clinical Professor of Medicine Emeritus, Stanford University School of Medicine (Stanford); Senior Attending Physician, Santa Clara Valley Medical Center (San Jose).

Richard Cohen, MD, MPH

Assistant Clinical Professor, Division of Occupational Medicine, University of California (San Francisco).

Wayne W. Deatsch, MD

Clinical Professor of Otorhinolaryngology, University of California (San Francisco).

Robert H. Dreisbach, MD, PhD

Clinical Professor of Environmental Health, School of Public Health and Community Medicine, University of Washington (Seattle).

John M. Erskine, MD

Associate Clinical Professor of Surgery, University of California (San Francisco); Associate in Surgery, Stanford University School of Medicine (Stanford).

Lawrence Z. Feigenbaum, MD

Clinical Professor of Medicine, University of California (San Francisco); Director of Professional Services and Medical Education and Director of Institute on Aging, Mount Zion Hospital and Medical Care Center (San Francisco).

Armando E. Giuliano, MD

Associate Professor of Surgery, University of California School of Medicine (Los Angeles).

Robert S. Goldsmith, MD, MPH, DTM&H

Professor of Tropical Medicine and Epidemiology, University of California (San Francisco).

Sadja Greenwood, MD, MPH

Assistant Clinical Professor of Obstetrics, Gynecology, and Reproductive Sciences, University of California (San Francisco).

Moses Grossman, MD

Professor of Pediatrics, University of California (San Francisco); Chief of Pediatrics, San Francisco General Hospital.

F. Carl Grumet, MD

Associate Professor of Pathology, Stanford University School of Medicine (Stanford).

Carlyn Halde, PhD

Associate Professor of Microbiology and Immunology, University of California (San Francisco).

Ernest Jawetz, MD, PhD

Professor of Microbiology and Medicine Emeritus, University of California (San Francisco).

John H. Karam, MD

Professor of Medicine, Co-director of Diabetes Clinic, and Chief of Clinical Endocrinology, University of California (San Francisco).

C. Michael Knauer, MD

Chief of Division of Gastroenterology, Santa Clara Valley Medical Center (San Jose); Clinical Professor of Medicine, Stanford University School of Medicine (Stanford).

Felix O. Kolb, MD

Clinical Professor of Medicine, University of California (San Francisco).

Margaret S. Kosek, MD

Staff Physician, Palo Alto Medical Foundation (Palo Alto).

Marcus A. Krupp, MD

Clinical Professor of Medicine Emeritus, Stanford University School of Medicine (Stanford); Director (Emeritus) of Research Institute, Palo Alto Medical Foundation (Palo Alto).

Joseph LaDou, MD

Associate Clinical Professor of Medicine and Acting Chief, Division of Occupational Medicine, University of California (San Francisco).

Alan J. Margolis, MD

Professor of Obstetrics, Gynecology, and Reproductive Sciences, University of California (San Francisco).

Alexander R. Margulis, MD

Professor and Chairman, Department of Radiology, University of California (San Francisco).

Kent R. Olson, MD

Assistant Clinical Professor of Medicine and Adjunct Lecturer in Pharmacy, University of California (San Francisco); Director of San Francisco Bay Area Regional Poison Center (San Francisco).

Rees B. Rees, Jr., MD

Clinical Professor of Dermatology Emeritus, University of California (San Francisco).

Sydney E. Salmon, MD

Professor of Internal Medicine, Hematology and Oncology, University of Arizona College of Medicine (Tucson); Director of Arizona Cancer Center.

Steven A. Schroeder, MD

Professor of Medicine and Chief, Division of General Internal Medicine, University of California (San Francisco).

Martin A. Shearn, MD

Clinical Professor of Medicine, University of California (San Francisco).

John B. Shinn, MD

Clinical Professor of Surgery, Stanford University School of Medicine (Stanford); Chief of Division of Otolaryngology, Head and Neck Surgery, Santa Clara Valley Medical Center (San Jose).

Sol Silverman, Jr., DDS

Professor of Oral Medicine and Chairman of the Division, University of California (San Francisco).

Maurice Sokolow, MD

Professor of Medicine Emeritus and Senior Staff Member, Cardiovascular Research Institute, University of California (San Francisco).

John L. Stauffer, MD

Associate Professor of Medicine, Milton S. Hershey Medical Center, Pennsylvania State University (Hershey, Pennsylvania).

Daniel P. Stites, MD

Professor of Laboratory Medicine and Director of Immunology Laboratory, University of California (San Francisco).

Samuel Strober, MD

Professor of Medicine and Chief of Division of Immunology, Stanford University School of Medicine (Stanford).

Lawrence M. Tierney, Jr., MD

Professor of Medicine, University of California (San Francisco); Assistant Chief of Medical Service Veterans Administration Medical Service (San Francisco).

Daniel Vaughan, MD

Clinical Professor of Ophthalmology, University of California (San Francisco); Member, Francis I. Proctor Foundation for Research in Ophthalmology.

Ralph O. Wallerstein, MD

Clinical Professor of Medicine, University of California (San Francisco).

Preface

Current Medical Diagnosis & Treatment 1987 is a comprehensive general medical text designed to serve the complete physician as his or her single most reliable source of information on adult diseases. Practical information on the management of patients is emphasized, along with appropriate background information to facilitate conceptual understanding.

OUTSTANDING FEATURES

- Revised and updated annually to maintain current relevance to daily problems of medical practice.
- In addition to covering all aspects of internal medicine, also includes chapters on obstetrics and gynecology, dermatology, ophthalmology, neurology, and other subjects of concern to the office practitioner.
- Over 1000 diseases and disorders.
- Consistent readable format, permitting efficient use in multiple clinical settings.
- Drug side effects and dosage adjustment for maximal therapeutic efficacy.
- Selected references for further investigation.
- Equally useful in inpatient and outpatient setting.

INTENDED AUDIENCE

Internists, family physicians, and other specialists will find *CMDT* useful as a ready reference and refresher text.

General surgeons, surgical specialists, obstetricians, gynecologists—all physicians and dentists—will find the book useful as a basic treatise on internal medicine, particularly the chapters on metabolism, endocrinology, cardiology, nephrology, geriatrics, and infectious diseases.

Students will find the book to be a reliable, authoritative introduction to medicine, with references that introduce them to a wide body of relevant literature.

House officers will find the concise discussions of diseases and the up-to-date references useful in the immediate management of patients.

Nurses and other health practitioners will find that the concise format and broad scope of the book facilitate their understanding of diagnostic procedures and rational therapy.

ORGANIZATION

This book is organized primarily by organ system. The sections on differential diagnosis refer to other systems where appropriate.

Chapters 1–3 present general information on patient care, including special problems of the elderly patient and prevention of disease. Chapters 4–19 present diseases and disorders according to specific organ systems. Chapter 20 discusses general problems of nutrition and metabolism. Chapters 21–27 cover infectious diseases, and Chapter 28 presents the latest information about anti-infective chemotherapy. Chapters 29–33 cover special topics: physical agents, poisoning, genetics in medical practice, malignant disorders, and immunologic disorders. The appendix provides data on normal values of daily interest in medical practice, as well as sections on imaging techniques, cardiopulmonary resuscitation, and the emergency treatment of airway obstruction.

NEW TO THIS EDITION

- Latest information on AIDS.
- Current indications for MRI and CT.
- A new chapter on nutrition.
- A revised chapter on genetic disorders, including new information on oncogenes and genetic counseling.
- A substantially revised first chapter on general care, including a section on disease prevention.
- Comments on chronic Epstein-Barr virus infection.
- A new section on angiodysplasia of the bowel.
- Major revision of the chapter on immunologic disorders, with a new section on clinical organ transplantation.
- Drug information and bibliographies updated through August 1986.

ACKNOWLEDGMENTS

The widespread distribution of this book overseas, both in translation and in its English language editions, has been a source of satisfaction to all who have worked on it over the years. We wish to express our thanks to our associate authors for participating so effectively in

the annual effort of updating and to the many students and physicians who have made useful suggestions for this and previous editions.

With the appearance of the 1987 edition, MAK and LMT welcome Dr Steven A. Schroeder as a new coeditor, succeeding Dr Milton J. Chatton, who for a quarter of a century contributed so creatively and unflaggingly to the success of the book.

We continue to solicit comments and recommen-

dations for future editions. Correspondence should be addressed to us at Lange Medical Publications, P.O. Drawer L, Los Altos, CA 94023.

Marcus A. Krupp
Lawrence M. Tierney, Jr.
Steven A. Schroeder

February, 1987

Table of Contents

Authors	xi
Preface	xiii
1. General Care—Symptoms & Disease Prevention	1
<i>Steven A. Schroeder, MD, & Milton J. Chatton, MD</i>	
Pain 1	
Fever & Hyperthermia 4	
Weight Loss 6	
Fatigue 6	
Shock Syndrome 7	
Systemic Allergic Reactions 12	
Disease Prevention 15	
2. Geriatric Medicine & the Elderly Patient	18
<i>Lawrence Z. Feigenbaum, MD</i>	
History Taking With Elderly Patients 18	
Physical Examination 19	
Mental Status Examination 19	
Evaluation of Functional Capacity 20	
Laboratory Examinations 20	
Special Clinical Considerations 20	
The Frail Elderly & the Five I's 21	
Summary 25	
3. Fluid & Electrolyte Disorders	28
<i>Marcus A. Krupp, MD</i>	
Basic Facts & Terms 28	
Physiology of Water & Electrolyte & Treatment of Abnormal States 29	
Pharmacologic Activity of Fluids & Electrolytes 33	
The Approach to Diagnosis & Treatment of Water, Electrolyte, & Acid-Base Disturbances 42	
4. Skin & Appendages	48
<i>Rees B. Rees, Jr., MD</i>	
Pruritus 49	
Common Dermatoses 50	
Viral Infections of the Skin 71	
Bacterial Infections of the Skin 74	
Fungal Infections of the Skin 77	
Parasitic Infestations of the Skin 84	
Tumors of the Skin 87	
Miscellaneous Skin, Hair, & Nail Disorders 89	
5. Eye	95
<i>Daniel Vaughan, MD</i>	
Nonspecific Manifestations of Eye Diseases 95	
Ocular Emergencies 96	
Common Ocular Disorders 100	

6. Ear, Nose, & Throat	111
<i>Wayne W. Deatsch, MD, & John B. Shinn, MD</i>	
Diseases of the Ear	111
Diseases of the Nose	118
Diseases of the Pharynx	122
Diseases of the Larynx	125
Foreign Bodies in the Air & Food Passages	127
7. Pulmonary Diseases	129
<i>John L. Stauffer, MD, & Jerome E. Carbone, MD</i>	
Diagnostic Methods	129
Developmental Disorders	131
Disorders of the Airways	132
Pleuropulmonary Infections	141
Neoplastic & Related Diseases	148
Interstitial Lung Diseases	154
Miscellaneous Infiltrative Lung Diseases	157
Disorders of the Pulmonary Circulation	159
Disorders Due to Chemical & Physical Agents	165
Disorders of Ventilation	171
Acute Respiratory Failure	173
Adult Respiratory Distress Syndrome (ARDS)	176
Pleural Diseases	177
8. Heart and Great Vessels	183
<i>Maurice Sokolow, MD</i>	
Nonspecific Manifestations	183
Functional Classification of Heart Disease	185
Congenital Heart Diseases	185
Acquired Heart Diseases	190
Disturbances of Rate & Rhythm	228
Disturbances of Conduction	236
Cardiac Failure	240
Diseases of the Pericardium	250
Diseases of the Myocardium	253
The Cardiac Patient & Surgery	261
The Cardiac Patient & Pregnancy	261
9. Blood Vessels & Lymphatics	263
<i>John M. Erskine, MD, & Lawrence M. Tierney, Jr., MD</i>	
Arterial Diseases	263
Disease of the Aorta	263
Atherosclerotic Occlusive Disease	267
Vasomotor Disorders	277
Venous Diseases	280
Diseases of the Lymphatic Channels	289
10. Blood	291
<i>Ralph O. Wallerstein, MD</i>	
Anemias	291
Leukemias	312
Lymphomas	317
Hemorrhagic Disorders	327
Blood Transfusions	337
11. Alimentary Tract & Liver	341
<i>C. Michael Knauer, MD, & Sol Silverman, Jr., DDS</i>	
Diseases of the Mouth	349
Diseases of the Esophagus	354
Diseases of the Stomach	361
Diseases of the Intestines	371
Diseases of the Colon & Rectum	382
Anorectal Diseases	392
Diseases of the Liver & Biliary Tract	395

Diseases of the Pancreas	420
Acute Peritonitis	424
12. Breast	427
<i>Armando E. Giuliano, MD</i>	
Carcinoma of the Female Breast	427
Carcinoma of the Male Breast	441
Mammary Dysplasia	442
Fibroadenoma of the Breast	443
Differential Diagnosis of Nipple Discharge	443
Fat Necrosis	444
Breast Abscess	444
Gynecomastia	444
13. Gynecology & Obstetrics	445
<i>Alan J. Margolis, MD, & Sadjia Greenwood, MD, MPH</i>	
14. Arthritis & Musculoskeletal Disorders	492
<i>Martin A. Shearn, MD</i>	
Connective Tissue (Collagen) Diseases	493
Vasculitic Syndromes	503
Seronegative Arthropathies	505
Degenerative Joint Disease	508
Neurogenic Arthropathy	509
Acute Bacterial (Septic) Arthritis	510
Other Infectious Arthropathies	511
Infections of Bones	511
Pain Syndromes	514
Tumors & Tumorlike Lesions of Bone	525
Other Disorders of Bones & Joints	526
General Principles in the Physical Management of Arthritic Joints	527
Total Joint Arthroplasty	530
15. Genitourinary Tract	532
<i>Marcus A. Krupp, MD</i>	
Disorders of the Kidneys	534
Infections of the Urinary Tract (by Ernest Jawetz, MD, PhD)	554
Urinary Stones	560
Tumors of the Genitourinary Tract	566
16. Nervous System	571
<i>Michael J. Aminoff, MD, FRCP</i>	
Headache	571
Facial Pain	574
Epilepsy	575
Transient Ischemic Attacks, Stroke	580
Intracranial & Spinal Space-Occupying Lesions	589
Selected Neurocutaneous Diseases	594
Movement Disorders	595
Dementia	600
Vertigo	601
Multiple Sclerosis	602
Acute Disseminated Encephalomyelitis	603
Spasticity	603
Subacute Combined Degeneration of the Spinal Cord	604
Wernicke's Encephalopathy	604
Stupor & Coma	604
Head Injury	607
Spinal Trauma	608
Syringomyelia	608
Motor Neuron Diseases	609
Peripheral Neuropathies	610
Neck & Back Pain	616
Brachial Plexus Lesions	618
Disorders of Neuromuscular Transmission	618
Myopathic Disorders	620
Periodic Paralysis Syndrome	621

17. Psychiatric Disorders	623
<i>James J. Brophy, MD</i>	
Psychiatric Assessment	624
Treatment Approaches	625
Common Psychiatric Disorders	641
Substance Use Disorders	661
Organic Mental Disorders	668
Geriatric Psychiatric Disorders	670
Death & Dying	672
Psychiatric Problems Associated With Medical & Surgical Disorders	673
18. Endocrine Disorders	677
<i>Carlos A. Camargo, MD, & Felix O. Kolb, MD</i>	
Common Presenting Complaints	678
Diseases of the Hypothalamus & of the Pituitary Gland	684
Diseases of the Thyroid Gland	692
The Parathyroids	708
Diseases of the Adrenal Cortex	722
Diseases of the Adrenal Medulla	733
Diseases of the Pancreatic Islet Cells	735
Diseases of the Testes	735
Diseases of the Ovaries	739
Disorders of Pluriglandular Involvement	744
Clinical Use of Corticotropin (ACTH) & the Corticosteroids	746
19. Diabetes Mellitus, Hypoglycemia, & Lipoprotein Disorders	749
<i>John H. Karam, MD</i>	
20. Nutrition	782
<i>Robert B. Baron, MD</i>	
Nutritional Requirements	782
Assessment of Nutritional Status	791
Protein-Calorie Undernutrition	795
Obesity	797
Eating Disorders	800
Disorders of Vitamin Metabolism (by Milton J. Chatton, MD)	801
Diet Therapy	806
Nutritional Support	809
21. Introduction to Infectious Diseases	815
<i>Ernest Jawetz, MD, PhD, & Moses Grossman, MD</i>	
22. Infectious Diseases: Viral & Rickettsial	834
<i>Moses Grossman, MD, & Ernest Jawetz, MD, PhD</i>	
23. Infectious Diseases: Bacterial	856
<i>Moses Grossman, MD, & Ernest Jawetz, MD, PhD</i>	
24. Infectious Diseases: Spirochetal	883
<i>Moses Grossman, MD, & Ernest Jawetz, MD, PhD</i>	
25. Infectious Diseases: Protozoal	894
<i>Robert S. Goldsmith, MD, MPH, DTM&H</i>	
26. Infectious Diseases: Helminthic	921
<i>Robert S. Goldsmith, MD, MPH, DTM&H</i>	
27. Infectious Diseases: Mycotic	950
<i>Carlyn Halde, PhD</i>	
28. Anti-infective Chemotherapeutic & Antibiotic Agents	959
<i>Ernest Jawetz, MD, PhD</i>	
Penicillins	961
Cephalosporins	965
Erythromycin Group	966

Tetracycline Group	967
Chloramphenicol	968
Aminoglycosides	969
Polymyxins	972
Antituberculosis Drugs	973
Sulfonamides & Antifolate Drugs	976
Sulfones Used in the Treatment of Leprosy	977
Specialized Drugs Against Bacteria	978
Urinary Antiseptics	979
Systemically Active Drugs in Urinary Tract Infections	979
Antifungal Drugs	980
Antimicrobial Drugs Used in Combination	981
Antimicrobial Chemoprophylaxis	982
Antiviral Chemotherapy	984
29. Disorders Due to Physical Agents	986
<i>Milton J. Chatton, MD</i>	
Disorders Due to Cold	986
Disorders Due to Heat	989
Burns (by R. Laurence Berkowitz, MD)	991
Electric Shock	996
Ionizing Radiation Reactions	997
Drowning	999
Other Disorders Due to Physical Agents	1000
30. Poisoning	1005
<i>Kent R. Olson, MD, & Robert H. Dreisbach, MD, PhD</i>	
Diagnosis of Poisoning	1005
Principles of Treatment of Poisoning	1008
Treatment of Common Specific Poisonings	1011
Treatment of Other Specific Poisonings	1024
Air Pollution & Smoking	1027
Environmental Hazards	1028
31. Medical Genetics	1030
<i>Margaret S. Kosek, MD</i>	
Chromosomal Disorders	1038
Selected Hereditary Metabolic Diseases	1044
32. Malignant Disorders	1053
<i>Sydney E. Salmon, MD</i>	
The Paraneoplastic Syndromes	1053
Diagnosis & Treatment of Emergencies & Complications of Malignant Disease	1054
Systemic Cancer Therapy	1059
33. Immunologic Disorders	1070
<i>Daniel P. Stites, MD, Samuel Strober, MD, & F. Carl Grumet, MD</i>	
Immunoglobulins & Antibodies: Humoral Immunity	1070
Cellular Immunity	1073
Immunologic Deficiency Diseases	1076
Immunogenetics & Transplantation	1080
Appendix	1085
Chemical Constituents of Blood & Body Fluids	1085
Normal Laboratory Values	1099
The Present Uses of Magnetic Resonance Imaging as Compared With Computed Tomography (by Alexander R. Margulis, MD)	1103
Cardiopulmonary Resuscitation	1105
Schedules of Controlled Drugs	1110
Nomograms	1111
Death Rate	1112
Conversion Tables	1113
Index	1115

General Care—Symptoms & Disease Prevention

1

Steven A. Schroeder, MD, & Milton J. Chatton, MD

PAIN

Approach to the Patient

Pain is the most common symptom causing patients to seek medical attention. Acute pain is often a manifestation of tissue injury and can provide the clinician with important diagnostic information. One should elicit and record information about the timing, nature, location, and radiation of pain and should note any aggravating or alleviating factors. Pain is a highly subjective phenomenon, and the patient's description may be difficult to interpret without careful questioning and amplification.

Many emotional and cultural factors influence the perception of pain. It is essential to try to establish the primary cause (eg, trauma, infection), pathogenesis (eg, inflammation, ischemia), and contributory factors (eg, recent changes in life situation, symbolic attributes of pain).

The management of pain must be individualized, depending on its severity, chronicity, and probable cause. Administration of a systemic analgesic is the usual method of management, but many other forms of pain control are available and should be used in appropriate circumstances.

Chronic Severe Pain

Awareness of the many pain control resources available is of special importance in managing the intractable pain of terminal cancer. Selection of drugs and dosages is critical in managing chronic severe pain, especially in difficult cases requiring a team effort. Examples of methods available for pain control are graded physical activity, simple reassurance, support groups, biofeedback training, and transcutaneous electrical nerve stimulation.

ANALGESIC AGENTS

1. DRUGS FOR SEVERE PAIN

The addicting analgesics—narcotics, opioids—are indicated for severe pain that cannot be relieved with less effective agents and threatens to cause systemic

shock. Examples are the pain of severe trauma, myocardial infarction, and ureteral stone and the pain that occurs postsurgery. Table 1-1 lists the addicting analgesics with some of their characteristics.

• These drugs have pharmacologic similarities to opium. They are employed principally for the control of severe pain, but they also act to suppress severe cough and diarrhea. All can produce **physical dependence** ("addiction"), but to varying degrees and after varying periods of use. The risk of addiction or habituation should not prevent their appropriate use, especially in the management of terminal illness.

A common error in management of pain from cancer is to prescribe insufficient doses "as necessary" rather than adequate doses around-the-clock at stated intervals. In such cases, the major goal of management should be patient comfort.

The "Brompton cocktail," a mixture of heroin or morphine, cocaine, a phenothiazine, alcohol, and chloroform water for oral administration, was widely publicized as an effective analgesic in British hospitals. Subsequent studies have shown that morphine alone is just as effective. Whether heroin—currently unavailable for prescription use in the USA—is superior to morphine is still controversial.

The effects of narcotics are reversed by naloxone and similar antagonists.

Tolerance

Continued use of narcotics produces tolerance—ie, increasing doses are needed to produce the same analgesic effect.

Contraindications

The narcotic drugs are contraindicated in some acute illnesses. In suspected acute abdomen, for example, the pattern of pain provides important diagnostic clues; and in acute head injuries these drugs interfere with clinical interpretation of neurologic changes.

Adverse Effects

The drugs in this category have the adverse effects listed below, though not to the same degree in all cases. Patients with hypothyroidism, adrenal insufficiency, hypopituitarism, reduced blood volume, and severe debility are particularly apt to suffer adverse effects from the addicting analgesics.

(1) Opioid narcotics should not be given to pa-

Table 1-1. Useful narcotic analgesics.*

	Approximate Equivalent Dose (mg)	Oral:Parenteral Potency Ratio	Duration of Analgesia (hours)	Maximum Efficacy	Addiction/Abuse Liability
Morphine	10	Low	4-5	High	High
Hydromorphone (Dilaudid)	1.5	Low	4-5	High	High
Oxymorphone (Numorphan)	1.5	Low	3-4	High	High
Methadone (Dolophine)	10	High	4-6	High	High
Meperidine (Demerol)	60-100	Low	2-4	High	High
Codeine	30-60†	High	3-4	Low	Medium
Oxycodone‡ (Percodan)	4.5†	Medium	3-4	Moderate	Medium
Dihydrocodeine (Drocode)	16	Medium	3-4	Moderate	Medium
Propoxyphene (Darvon)	60-120†	Oral use only	4-5	Very low	Low/medium
Pentazocine (Talwin)	30-50†	Medium	3-4	Moderate	Low/medium

*Modified and reproduced, with permission, from Katzung BG (editor): *Basic & Clinical Pharmacology*, 3rd ed. Appleton-Lange, 1987.

†Analgesic efficacy at this dose not equivalent to 10 mg of morphine. See text for explanation.

‡Available only in tablets containing aspirin (Percodan) or acetaminophen (Percocet).

tients with pulmonary insufficiency, because of dose-dependent respiratory depression.

(2) Central nervous system effects include sedation, euphoria, nausea, and vomiting. Antidepressants, antihistamines, phenothiazines, and hypnotics can potentiate these effects.

(3) Cardiovascular effects of particular importance are hypotension and circulatory collapse.

(4) Gastrointestinal effects are chiefly decrease in bowel motility and consequent severe constipation.

(5) Genitourinary effects include bladder spasm and urinary retention.

(6) Hepatic and biliary effects include enhanced sensitivity to the drugs, in patients with hepatic insufficiency; and biliary spasm, resulting in severe biliary colic.

(7) Allergic manifestations also occur.

Frequently Used Addictive Analgesics

A. Morphine Sulfate, 8-15 mg subcutaneously or intramuscularly, is the most effective drug for control of severe pain. The effects last 4-5 hours. In acute myocardial infarction or acute pulmonary edema in left ventricular failure, 2-6 mg may be injected slowly intravenously in 5 mL of saline solution.

Morphine produces significant respiratory depression, raises intracranial pressure, and may induce vomiting, which means that patients must be monitored during the period of the drug's effect.

B. Morphine Congeners give effects equivalent to 10 mg of morphine sulfate but have no specific advantages. Give either hydromorphone or oxymorphone, 2-4 mg orally every 4 hours or 1-3 mg subcutaneously every 4 hours.

C. Meperidine (Demerol), 50-150 mg orally or intramuscularly every 3-4 hours, provides analgesia similar to that achieved with morphine. Its indications and side effects are similar to those of morphine.

D. Methadone, 10 mg orally, is most often used for serious addiction and for treatment of chronic pain, as may be necessary in management of a patient with metastatic cancer. Its side effects are similar to those of morphine, but tolerance and physical dependence are slower to develop.

E. Codeine (sulfate or phosphate), 15-65 mg orally or subcutaneously every 4-6 hours, is somewhat less effective than morphine but also less habit-forming. It is often given together with aspirin or acetaminophen for enhanced analgesic effect. Codeine is a powerful cough suppressant in a dose of 15-30 mg orally every 4 hours but is constipating.

F. Dihydrocodeine is similar to codeine but more potent. Smaller doses are used (16 mg every 4-6 hours).

G. Oxycodone is for oral use and is always prescribed with another analgesic. The dosage is 5 mg every 4-6 hours in tablets that contain aspirin (Percodan) or acetaminophen (Percocet).

H. Propoxyphene (Darvon), 75 mg orally every 4-6 hours, has an analgesic effect little better than that of aspirin, but the side effects are minimal. When the drug is combined with aspirin or acetaminophen, the analgesic action is enhanced but is still similar to optimal doses of aspirin. Compared with other drugs in this category, it has a low potential for addiction.

I. Pentazocine (Talwin), 50 mg orally or 30 mg intramuscularly every 3-4 hours, is one of a group of agonist-antagonist opioids—ie, it can induce with-

drawal symptoms in addicts while also having a morphinelike action. It has moderate analgesic action. These drugs—others are nalbuphine (Nubain) and buporphanol (Stadol)—offer little advantage, can cause addiction, and are less effective analgesics than morphine. They should ordinarily not be used.

2. DRUGS FOR MODERATE PAIN

What constitutes “moderate pain” is a difficult semantic and clinical distinction perhaps best defined in terms something like this: If a responsible patient has enough pain to cause him to seek medical consultation but not enough pain to elicit a prescription for morphine from a responsible physician, the pain is moderate. Most people can manage their minor aches and pains with OTC analgesics available at the drug store or food store. Drugs such as codeine, oxycodone, and pentazocine, listed above as “addictive narcotics,” are sometimes used for moderate pain, but salicylates or acetaminophen in higher doses or the highly visible class of NSAIDs are often better for this purpose. (See Table 1–2.)

The activity—both anti-inflammatory and analgesic—of aspirin, acetaminophen, and the NSAIDs is mediated through inhibition of the biosynthesis of prostaglandins. All of these drugs to varying degrees inhibit prothrombin synthesis and platelet aggregation, may cause gastric irritation and kidney damage, and may give rise to allergic reaction. All NSAIDs are analgesic, antipyretic, and anti-inflammatory in dose-dependent fashion. For example, ibuprofen has analgesic actions at 200 mg and analgesic plus anti-inflammatory actions at 400 mg. Their principal uses are in the control of moderate pain of arthritis (rheuma-

toid, degenerative, etc), other musculoskeletal disorders, menstrual cramps, and other—mainly self-limited—conditions, including moderate postoperative discomfort.

Table 1–2 lists the most commonly used NSAIDs along with dosages and pertinent comments.

3. DRUGS FOR MILD PAIN

The ability to tolerate minor degrees of discomfort varies greatly in different individuals. Most people prefer to relieve rather than endure pain, using analgesics by the millions of tons each year for the treatment of headaches, the discomfort of minor respiratory infections, muscle aches, etc. The most widely used agents for these purposes are aspirin and acetaminophen.

Aspirin is the drug of first choice for management of mild to moderate pain and is an effective antipyretic and anti-inflammatory agent. It is available in many forms for oral administration in a single 325-mg unit dose, as well as smaller (eg, 60 mg) and larger (eg, 500 mg) doses. The usual dose is 2 tablets (650 mg) every 4 hours as needed, taken with fluid. Gastrointestinal irritation can be reduced by ingestion with milk or other food or with an antacid. Enteric-coated aspirin (Ecotrin; many others) can be used to avoid gastric irritation, but absorption is delayed.

The main untoward effect of aspirin—especially in large doses or when taken chronically—is gastric irritation and microscopic blood loss from the gut. Rarely, there may be massive gastrointestinal hemorrhage, most commonly in heavy drinkers, or patients being given corticosteroids, or patients with a history of peptic ulcer disease.

Table 1–2. Useful nonsteroidal anti-inflammatory drugs.

Generic Name	Proprietary Name	Dosage Range	Comments*
Fenoprofen	Nalfon	300–600 mg 3–4 times daily	
Ibuprofen	Advil (OTC), Motrin, etc	200–600 mg 3–4 times daily	Now available without prescription; relatively well tolerated.
Indomethacin	Indameth, Indocin, etc	25–50 mg 2–4 times daily	Prototype untoward effects: headache, tinnitus, dizziness, confusion, rashes, anorexia, nausea, vomiting, gastrointestinal bleeding, diarrhea, nephrotoxicity, visual disturbances, etc.
Meclofenamate sodium	Meclomen	100 mg 2–4 times daily	Diarrhea relatively more common.
Naproxen	Anaprox, Naprosyn	250–500 mg twice daily	Useful for menstrual cramps.
Piroxicam	Feldene	20 mg daily	Single dosage convenient; relatively expensive; may have higher rate of gastrointestinal bleeding.
Sulindac	Clinoril	150–200 mg twice daily	Adverse effects similar to those of indomethacin; relatively expensive.
Tolmetin	Tolectin	200–600 mg 4 times daily	

*The adverse effects listed for indomethacin and others can occur with any of the drugs that have been available for shorter periods. Tolerance and efficacy are subject to great individual variations among patients.